van Doorn PA - Search Results

1

Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS).

van Doorn PA. van Doorn PA. Presse Med. 2013 Jun;42(6 Pt 2):e193-201. doi: 10.1016/j.lpm.2013.02.328. Epub 2013 Apr 28. Presse Med. 2013. PMID: 23628447 Review.

2

Treatment of immune neuropathies.

Van Doorn PA, Garssen MP. Van Doorn PA, et al. Curr Opin Neurol. 2002 Oct;15(5):623-31. doi: 10.1097/00019052-200210000-00014. Curr Opin Neurol. 2002. PMID: 12352007 Review.

3

Immunotherapy for Guillain-Barré syndrome.

van Doorn PA, van Koningsveld R. van Doorn PA, et al. Among authors: van koningsveld r. Lancet Neurol. 2004 Feb;3(2):84. doi: 10.1016/s1474-4422(03)00660-4. Lancet Neurol. 2004. PMID: 14746999 Review. No abstract available.

4

Functional polymorphisms in LPS receptors CD14 and TLR4 are not associated with disease susceptibility or Campylobacter jejuni infection in Guillain-Barré patients.

Geleijns K, Jacobs BC, Van Rijs W, Tio-Gillen AP, Laman JD, van Doorn PA. Geleijns K, et al. Among authors: van rijs w, van doorn pa. J Neuroimmunol. 2004 May;150(1-2):132-8. doi: 10.1016/j.jneuroim.2004.01.003. J Neuroimmunol. 2004. PMID: 15081257

5

Fas polymorphisms are associated with the presence of anti-ganglioside antibodies in Guillain-Barre syndrome.

Geleijns K, Laman JD, van Rijs W, Tio-Gillen AP, Hintzen RQ, van Doorn PA, Jacobs BC. Geleijns K, et al. Among authors: van rijs w, van doorn pa. J Neuroimmunol. 2005 Apr;161(1-2):183-9. doi: 10.1016/j.jneuroim.2004.12.001. J Neuroimmunol. 2005. PMID: 15748958

6

Treatment of Guillain-Barré syndrome and CIDP.

van Doorn PA. van Doorn PA. J Peripher Nerv Syst. 2005 Jun;10(2):113-27. doi: 10.1111/j.1085-9489.2005.0010203.x. J Peripher Nerv Syst. 2005. PMID: 15958124 Review.

7

Distinguishing acute-onset CIDP from Guillain-Barré syndrome with treatment related fluctuations.

Ruts L, van Koningsveld R, van Doorn PA. Ruts L, et al. Among authors: van koningsveld r, van doorn pa. Neurology. 2005 Jul 12;65(1):138-40. doi: 10.1212/01.wnl.0000167549.09664.b8. Neurology. 2005. PMID: 16009902

8

Diagnostic value of anti-GM1 ganglioside serology and validation of the INCAT-ELISA.

Kuijf ML, van Doorn PA, Tio-Gillen AP, Geleijns K, Ang CW, Hooijkaas H, Hop WC, Jacobs BC. Kuijf ML, et al. Among authors: van doorn pa. J Neurol Sci. 2005 Dec 15;239(1):37-44. doi: 10.1016/j.jns.2005.07.009. Epub 2005 Sep 8. J Neurol Sci. 2005. PMID: 16154154

9

Conduction velocity distribution in neurologically well-recovered but fatigued Guillain-Barré syndrome patients.

Garssen MP, Blok JH, van Doorn PA, Visser GH. Garssen MP, et al. Among authors: van doorn pa. Muscle Nerve. 2006 Feb;33(2):177-82. doi: 10.1002/mus.20451. Muscle Nerve. 2006. PMID: 16270305 Clinical Trial.

10

Mannose-binding lectin contributes to the severity of Guillain-Barré syndrome.

Geleijns K, Roos A, Houwing-Duistermaat JJ, van Rijs W, Tio-Gillen AP, Laman JD, van Doorn PA, Jacobs BC. Geleijns K, et al. Among authors: van rijs w, van doorn pa. J Immunol. 2006 Sep 15;177(6):4211-7. doi: 10.4049/jimmunol.177.6.4211. J Immunol. 2006. PMID: 16951387

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

427 results

Search Page

Filters